Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 15Breast 14Gastrointestinal 13Head & Neck 6Endocrine 6Thoracic 5Genitourinary 5Tumor-Agnostic 3Other 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1

Conditions

Intrathecal Dexmedetomidine 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Biopsy 9fludarabine phosphate 8Busulfan 8Whole-Body Irradiation 7Surveys and Questionnaires 6Mycophenolic Acid 6Educational Status 6Early Intervention, Educational 6Carboplatin 6fludarabine 5Tacrolimus 5Paclitaxel 5Methotrexate 5Methods 5Melphalan 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Colposcopy 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4Selenium 4Radiotherapy 4Patient Reported Outcome Measures 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dexmedetomidine × Other neoplasm × Clear all
NCT02861716 2018-04-10

Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine in Children Undergoing Major Abdominal Cancer Surgery

South Egypt Cancer Institute

Phase 2 Unknown
60 enrolled
Other neoplasm

Intrathecal Dexmedetomidine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡